Short answer: For regenerative medical products, Japan’s conditional and time-limited approval is permission to market a specific product for a specified use while further evidence is collected. Under Article 23-26 of the PMD Act, efficacy must be presumed and safety assessed, but confirmatory evidence remains outstanding. The approval holder must collect post-marketing data and re-apply within the granted period. This is a legally approved product, not merely an experimental intervention, but it is not standard approval or a guarantee of benefit 00033213000278074.pdf.
What does conditional approval require?
This article concerns Japan’s pathway for regenerative medical products, not every use of the term conditional approval. PMDA reviews product quality, safety and efficacy, and the Ministry of Health, Labour and Welfare (MHLW) grants approval. Article 23-26 sets out eligibility conditions, including product heterogeneity, presumed efficacy and an assessment of harmful effects relative to the intended benefit 00033213.

The pathway allows earlier access before confirmatory clinical trial results are available; it does not dispense with clinical evidence. PMDA’s guidance requires a plan to confirm efficacy and further assess safety after marketing. In principle, all treated patients are enrolled in post-marketing surveillance for evaluation of the approval conditions 000278074.pdf.
How long does it last?
The initial approval period cannot exceed seven years. An extension of up to three years is possible when particularly necessary for proper review, after the relevant council has been consulted; it is not automatic. The guidance calls for consultation with PMDA about an extension at least six months before the deadline 3213000278074.pdf.
The approval holder must re-apply within the granted period using the required evidence. If that application is awaiting a decision when the period ends, the existing approval remains effective until the decision. Refusal of standard approval ends that conditional approval 000278074.pdf.
How is it different from standard approval?
Conditional approval allows marketing with greater uncertainty about efficacy, subject to a time limit and further evaluation. Standard approval means the applicable approval requirements have been met; it does not mean every uncertainty has disappeared or every patient will benefit. Safety monitoring can continue after either type of approval 3213000278074.pdf.
Is a clinic’s treatment plan the same thing?
No. Japan’s registration and compliance rules for regenerative medicine include a separate route under the Act on the Safety of Regenerative Medicine. A provider submits a provision plan following review by a certified committee. That process is not a PMD Act marketing approval for a product, and a plan number alone does not establish that the treatment is effective 4980.
When assessing the regulatory information on a clinic’s website, distinguish a product approval from a treatment-plan filing or research participation. None of these labels, by itself, establishes that a proposed intervention is appropriate for your condition.
Which products illustrate the pathway?
PMDA’s review-report index records the following original conditional approvals. These are historical examples, not a list of treatments currently available to patients. The original approval month does not, by itself, confirm present authorization or supply 0004.
| Product | Product and original approved use | Original conditional approval |
|---|---|---|
| HeartSheet | Sheets made from the patient’s own skeletal myoblasts, surgically placed on the heart. The original indication was severe heart failure due to ischemic heart disease unresponsive to standard treatment, with NYHA class III or IV symptoms and resting left ventricular ejection fraction of 35% or less 000215222.pdf. | September 2015 0004. |
| Stemirac | The patient’s own bone-marrow-derived mesenchymal stem cells, administered intravenously. The original indication covered neurological symptoms and functional disorders from traumatic spinal cord injury assessed as AIS grade A, B or C; the instructions aimed for bone-marrow collection within 31 days of injury, depending on the patient’s condition 000231946.pdf. | December 2018 0004. |
| Delytact | Teserpaturev, an oncolytic virus product for malignant glioma, administered into the tumor under the original adult dosing instructions. It is not a stem cell infusion 000242808.pdf. | June 2021 0004. |
HeartSheet also shows why the distinction matters: PMDA records its September 2015 conditional approval and states that full approval was rejected as of 24 July 2024. The original approval was therefore not an assurance that the product would later receive standard approval 0004.
How can you check an approval claim?
Ask the provider for the exact product name, approved indication, administration route, approval type, time limit and evidence of its current status. Compare those details with PMDA’s review report and the current product information. Approval for one product and indication cannot establish approval for a different cell preparation, disease or delivery route 32130004.
A practical document check: In PMDA’s index, HeartSheet has both an original conditional-approval entry and a separate entry recording rejection of full approval. Reading only the first entry would miss the later outcome. Open the relevant documents and check for subsequent decisions, rather than relying on a saved approval date 0004.
For example, a claim about an intravenous stem cell treatment for chronic spinal cord injury cannot be validated simply by pointing to Stemirac’s original approval. Its review report specifies traumatic injury, AIS grades and a time-sensitive collection procedure. Those details must be checked against the proposed treatment, not assumed to match 000231946.pdf.
These examples explain how to read regulatory documents; they are not patient cases or evidence of personal clinical experience. A physician should explain the evidence, uncertainties and adverse effects relevant to the actual product and your medical circumstances.
Questions about treatment information in Japan?
Contact our support team with your questions. Product approval and individual suitability require separate verification.
Bottom line: Conditional approval is a real but time-limited product authorization with outstanding evidence requirements. Verify the named product, indication and latest decision; do not substitute a clinic’s plan number or an old approval announcement for that check 32130004.
This article concerns Japan’s regenerative-medical-product framework and provides general regulatory information, not personal medical advice. Historical approval details are not a recommendation or confirmation of current treatment availability.




